@FierceBiotech: J&J stays mum about cash, but biotech buyout is a landmark win for Index fund. Story | Follow @FierceBiotech
@JohnCFierce: Crohn's expert flags blockbuster potential--and frets--of Celgene's mongersen. News | Follow @JohnCFierce
@DamianFierce: Today begins the round of 64 in FierceMadness, a pointless & absurd tournament of drug names. More | Follow @DamianFierce
> Amicus Therapeutics ($FOLD) accelerated its plans to submit its lead drug for regulatory approval following some positive discussions with U.S. and European regulators. The company now plans file migalastat, a treatment for Fabry disease, in the second quarter. More
> Despite a value-destroying accounting scandal, two former Salix Pharmaceuticals ($SLXP) execs are walking away with $46 million thanks to Valeant Pharmaceuticals' ($VRX) pending $11.1 billion acquisition of the company, Bloomberg reports. News
> Daiichi Sankyo is paying $200 million up front to partner up on AstraZeneca ($AZN) and Nektar Therapeutics' ($NKTR) recently approved constipation drug Movantik, promising up to $625 million more depending on sales. Story
Medical Device News
@FierceMedDev: ICYMI: Vivo Capital doubles down to close $750M US-China healthcare fund. Story | Follow @FierceMedDev
@VarunSaxena2: Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Story | Follow @VarunSaxena2
@EmilyWFierce: Changes in public's perceptions of risk contributes to spread of infectious diseases, says NIAID director. More from The Atlantic | Follow @EmilyWFierce
> Boston Scientific subsidiary hit with $50M gender discrimination suit. Report
> Canon BioMedical makes first move with rapid DNA, drug metabolism diagnostic startup. Story
> Medtronic's stent for peripheral artery disease wins expanded indication from FDA. Article
Pharma News
@FiercePharma: Sanofi's Shantha ready to supply 37 million doses of long-delayed pentavalent. FierceVaccines story | Follow @FiercePharma
@EricPFierce: When it comes to Big Pharma revenues, who's the biggest of them all? Special report | Follow @EricPFierce
@CarlyHFierce: Don't forget that there are FOUR regions to vote in today - let's show the oncology drugs some love, shall we? More on FierceMadness | Follow @CarlyHFierce
> Sanofi's diabetes franchise one step closer to U.S. Lyxumia launch. More
> Daiichi shells out $200M-plus to help AstraZeneca launch Movantik. News
> Bristol-Myers chief's last 'paycheck' as CEO is a doozy at $27M. Article
CRO News
> Quintiles taps Google partner Tute Genomics for R&D. Item
> Trial tech outfit Clinical Ink merges with app upstart. News
> Evotec pairs up with Second Genome to gut out some R&D. More
> Catalent shakes up its business with an eye on product launches. Story
> WuXi dives into the CAR-T fray with new plant plans. Article
Vaccines News
> Cancer vaccine maker Aduro files for $86M IPO. Item
> Allergy Therapeutics scores $30M to finish grass allergy vaccine. More
> England to provide GSK MenW vaccine to 3 million teens. News
> GSK to test Ebola jab with booster from Emergent BioSolutions. Report
> More vaccines deals for Pfizer? It wouldn't say no, exec says. Story
Pharma Manufacturing News
> Puerto Rico manufacturing base to grow with AbbVie expansion. More
> Kite Pharma adds manufacturing assets with T-Cell Factory acquisition. Item
> India's Micro Labs recalls drugs made at banned plant. Report
> Wockhardt says FDA impressed by the strides it made at a banned plant. Article
> Lawsuit would force FDA to ban or label wheat gluten as ingredient. Story
Pharma Asia News
> U.S.-based lawsuits pile up for Japan's Olympus in superbug case. Item
> Indonesia drug industry investment lags despite universal insurance program. Article
> Daiichi Sankyo pays $200M to AstraZeneca for Movantik U.S. sales rights. Story
> U.S. FDA softens approach in meetings with Indian regulators. Report
> India's Wockhardt, Granules, suggest recent FDA inspections went well. More